Travere Therapeutics Inc (NASDAQ:TVTX) currently has a daily average trading volume of 1.60M but it saw 1118386 shares traded in last market. With a market cap of 1.81B USD, the company’s current market price of $20.37 came falling about -2.02 while comparing to the previous closing price of $20.79. In past 52 weeks, the stock remained buoying in the range of price level as high as $25.29 and as low as $5.12. In the recent trading on the day, stock has struck highest price mark of $20.34 while lowest mark touched by it was $21.18.
Taking a look at 20-day trading activity of Travere Therapeutics Inc (TVTX) gives us an average price of $19.88, while its current price level is -19.45% below from 52-week high level whereas it is 297.85% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $20.64 while that of 200 days or SMA-200 reads an average of $15.42. A closer look into the stock’s movement over the week reveals that its volatility is standing at 4.01% during that period while stretching the period over a month that increases to 5.05%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 49.95 which implies that the stock is in neutral territory.
Wells Fargo upgraded its recommendation for the stock as a “Overweight” from “Equal Weight” on October 21, 2024 while assigning a price target range of $9-$27.
Over the week, TVTX’s stock price is moving -2.21% down while it is -3.14% when we observe its performance for the past one month. Year-to-date it is 16.93% up and over the past year, the stock is showing an upside performance of 164.89%.
The company is expected to be releasing its next quarterly report on 2025-Feb-19, for which analysts forecasted an EPS of -0.36 while estimate for next year EPS is -0.33. In next quarter, company is expected to be making quarterly sales of $89.56M as analysts are expecting the sales for current fiscal year at $391.74M and seeing the company making $602.36M in sales next year. Moreover, analysts are in estimates of $77.53M for current-quarter revenue.
Currently, Travere Therapeutics Inc’s total number of outstanding shares is 87.45M with 0.63% of that held by the insiders while 109.23% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at -83.18% and return on equity (ROE) at -246.75%. It has a 24.21 of forward P/E ratio. Stock’s beta reads 0.78. Stock has a price to book (P/B) ratio of 30.15 while price to sale or P/S ratio amounts to 7.75. Its return on asset (ROA) is -46.37% on average.
